Our leaders
Determined to solve the intractable
Leadership Team
Board of Directors
Jeff Albers
Venture Partner, Atlas Venture
Jeff Albers has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. Mr. Albers currently serves as a Venture Partner at Atlas Venture, an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Since 2021, Mr. Albers has served as Chairperson of the Board of Directors of Blueprint Medicines and previously served as our President and Chief Executive Officer from 2014 to 2022, where he led the research-stage company through an initial public offering and evolved it into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Mr. Albers previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a wholly-owned subsidiary of Sanofi), including Vice President of the U.S. Hematology and Oncology business unit. Earlier in his career, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. Mr. Albers currently serves as a member of the Audit and Compensation Committees on the Board of Directors of Magenta Therapeutics and as the Chair of the Compensation Committee of the Board of Directors of Kymera Therapeutics. He holds a B.S. from Indiana University and an M.B.A. and J.D. from Georgetown University.
Jeff Albers has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. Mr. Albers currently serves as a Venture Partner at Atlas Venture, an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Since 2021, Mr. Albers has served as Chairperson of the Board of Directors of Blueprint Medicines and previously served as our President and Chief Executive Officer from 2014 to 2022, where he led the research-stage company through an initial public offering and evolved it into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Mr. Albers previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a wholly-owned subsidiary of Sanofi), including Vice President of the U.S. Hematology and Oncology business unit. Earlier in his career, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. Mr. Albers currently serves as a member of the Audit and Compensation Committees on the Board of Directors of Magenta Therapeutics and as the Chair of the Compensation Committee of the Board of Directors of Kymera Therapeutics. He holds a B.S. from Indiana University and an M.B.A. and J.D. from Georgetown University.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
Daniella Beckman has served on our Board of Directors since December 2021 and is Chair of the Audit Committee. Since 2019, Ms. Beckman has served as Chief Financial Officer of Tango Therapeutics, where she oversees finance, investor relations and business development. Prior to joining Tango, Ms. Beckman provided consulting services and served as Interim Chief Financial Officer for early-stage biotechnology companies from 2015 to 2019. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, where she was responsible for finance, investor relations and information technology until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceutical Group, Biogen and PricewaterhouseCoopers. Ms. Beckman also serves as Chair of the Audit Committee and member of the Compensation Committee for the Board of Directors of Vor Biopharma. She previously served as Chair of the Audit Committee and member of the Nomination and Governance Committee for the Board of Directors of 5:01 Acquisition Corp. and Chair of both the Audit and the Nomination and Governance Committees for the Board of Directors of Translate Bio. Ms. Beckman received a B.A. in business administration and accounting from Boston University.
Daniella Beckman has served on our Board of Directors since December 2021 and is Chair of the Audit Committee. Since 2019, Ms. Beckman has served as Chief Financial Officer of Tango Therapeutics, where she oversees finance, investor relations and business development. Prior to joining Tango, Ms. Beckman provided consulting services and served as Interim Chief Financial Officer for early-stage biotechnology companies from 2015 to 2019. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, where she was responsible for finance, investor relations and information technology until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceutical Group, Biogen and PricewaterhouseCoopers. Ms. Beckman also serves as Chair of the Audit Committee and member of the Compensation Committee for the Board of Directors of Vor Biopharma. She previously served as Chair of the Audit Committee and member of the Nomination and Governance Committee for the Board of Directors of 5:01 Acquisition Corp. and Chair of both the Audit and the Nomination and Governance Committees for the Board of Directors of Translate Bio. Ms. Beckman received a B.A. in business administration and accounting from Boston University.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Alexis Borisy
Co-Founder and Operating Chairman, Curie.Bio
Alexis Borisy has served as a member of our Board of Directors since April 2011. Mr. Borisy co-founded Blueprint Medicines and served as Interim Chief Executive officer from May 2013 through July 2014. Mr. Borisy is Co-Founder and Operating Chairman of Curie.Bio, Inc., a venture capital firm focused on helping entrepreneurial founders launch therapeutics companies. He also co-founded IDRx, Inc., a biopharmaceutical company focused on precision combination oncology therapies. Previously, Mr. Borisy was a partner at Third Rock Ventures, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Mr. Borisy currently serves as Chairman and member of the Audit, Compensation and Research and Development Committees of the Board of Directors of Relay Therapeutics, Inc. He also serves as Chairman and member of the Audit and Compensation Committees of the Board of Directors of Tango Therapeutics, Inc., and as a member of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors of Revolution Medicines, Inc. Mr. Borisy previously served on the Board of Directors of Magenta Therapeutics, Inc., Editas Medicine, Inc. and FORMA Therapeutics, Inc. and as Chairman of the Board of Directors at EQRx, Inc. Mr. Borisy co-founded Foundation Medicine, Inc., serving as Interim Chief Executive Officer from 2009 to 2011 and as Chairman of the Board of Directors from 2011 to 2017 until its acquisition by Roche. In 2000, Mr. Borisy founded CombinatoRx, Inc. and served as its Chief Executive Officer and as a member of its Board of Directors. Mr. Borisy received a B.S. in chemistry from the University of Chicago and an M.S. in chemistry and chemical biology from Harvard University.
Alexis Borisy has served as a member of our Board of Directors since April 2011. Mr. Borisy co-founded Blueprint Medicines and served as Interim Chief Executive officer from May 2013 through July 2014. Mr. Borisy is Co-Founder and Operating Chairman of Curie.Bio, Inc., a venture capital firm focused on helping entrepreneurial founders launch therapeutics companies. He also co-founded IDRx, Inc., a biopharmaceutical company focused on precision combination oncology therapies. Previously, Mr. Borisy was a partner at Third Rock Ventures, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Mr. Borisy currently serves as Chairman and member of the Audit, Compensation and Research and Development Committees of the Board of Directors of Relay Therapeutics, Inc. He also serves as Chairman and member of the Audit and Compensation Committees of the Board of Directors of Tango Therapeutics, Inc., and as a member of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors of Revolution Medicines, Inc. Mr. Borisy previously served on the Board of Directors of Magenta Therapeutics, Inc., Editas Medicine, Inc. and FORMA Therapeutics, Inc. and as Chairman of the Board of Directors at EQRx, Inc. Mr. Borisy co-founded Foundation Medicine, Inc., serving as Interim Chief Executive Officer from 2009 to 2011 and as Chairman of the Board of Directors from 2011 to 2017 until its acquisition by Roche. In 2000, Mr. Borisy founded CombinatoRx, Inc. and served as its Chief Executive Officer and as a member of its Board of Directors. Mr. Borisy received a B.S. in chemistry from the University of Chicago and an M.S. in chemistry and chemical biology from Harvard University.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Lonnel Coats
Former Chief Executive Officer, Lexicon Pharmaceuticals
Lonnel Coats has served as a member of our Board of Directors since February 2016 and is the Chair of the Nominating and Corporate Governance Committee. From 2014 to 2024, Mr. Coats served as Chief Executive Officer and a member of the Board of Directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company pioneering medicines for a range of diseases including neuropathic pain, heart failure, diabetes and metabolism. Prior to joining Lexicon, from 1996 to June 2014, Mr. Coats served in a series of leadership positions at Eisai, Inc. and Eisai Corporation of North America, both of which are U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., including as Chief Executive Officer of Eisai, Inc. from 2010 to June 2014 and as President and Chief Operating Officer of Eisai, Inc. from 2004 to 2010. Mr. Coats also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats currently serves as a member of the Audit Committee of the Board of Directors of Verve Therapeutics, Inc. Mr. Coats received a B.S. in public administration from Oakland University.
Lonnel Coats has served as a member of our Board of Directors since February 2016 and is the Chair of the Nominating and Corporate Governance Committee. From 2014 to 2024, Mr. Coats served as Chief Executive Officer and a member of the Board of Directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company pioneering medicines for a range of diseases including neuropathic pain, heart failure, diabetes and metabolism. Prior to joining Lexicon, from 1996 to June 2014, Mr. Coats served in a series of leadership positions at Eisai, Inc. and Eisai Corporation of North America, both of which are U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., including as Chief Executive Officer of Eisai, Inc. from 2010 to June 2014 and as President and Chief Operating Officer of Eisai, Inc. from 2004 to 2010. Mr. Coats also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats currently serves as a member of the Audit Committee of the Board of Directors of Verve Therapeutics, Inc. Mr. Coats received a B.S. in public administration from Oakland University.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Habib Dable
Part-time Venture Partner, RA Capital Management, L.P.
Habib Dable has served on our Board of Directors since June 2022. Mr. Dable is a versatile, patient-focused executive with approximately 28 years in “Big Pharma” and “Emerging Biotech” environments, currently a part-time Venture Partner at RA Capital Management, L.P. and an advisor for GLG Institute. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021 for $11.5B. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility, including President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, STIVARGA®, and XOFIGO®. He currently serves on the Board of Directors of PepGen, Inc. Mr. Dable received a B.B.A. in marketing and finance and an M.B.A. from the University of New Brunswick.
Habib Dable has served on our Board of Directors since June 2022. Mr. Dable is a versatile, patient-focused executive with approximately 28 years in “Big Pharma” and “Emerging Biotech” environments, currently a part-time Venture Partner at RA Capital Management, L.P. and an advisor for GLG Institute. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021 for $11.5B. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility, including President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, STIVARGA®, and XOFIGO®. He currently serves on the Board of Directors of PepGen, Inc. Mr. Dable received a B.B.A. in marketing and finance and an M.B.A. from the University of New Brunswick.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Mark Goldberg, M.D.
Lecturer in Medicine, Harvard Medical School and Faculty Member, Hematology Division, Brigham and Women’s Hospital
Mark Goldberg, M.D. has served as a member of our Board of Directors since June 2015. Since 2018, Dr. Goldberg has served as an advisor at CANbridge Life Sciences Ltd., a biopharmaceutical company focused on rare diseases and rare oncology, and served as Acting Chief Medical Officer from 2015 to 2018. Previously, he served as an advisor and held various executive positions of increasing responsibility at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals, Inc., including Executive Vice President, Medical and Regulatory Strategy. Earlier in his career, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme from November 1996 to July 2011, including as Senior Vice President, Clinical Development and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of the Early Product Development Board. Dr. Goldberg has been a faculty member of the Hematology Division at Brigham and Women’s Hospital since 1987 and was a staff physician at the Dana-Farber Cancer Institute from 1996 to 2018. From 1996 to 2021, Dr. Goldberg was a part-time Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg currently serves as a member of the Compensation and Governance and Nominating Committees of the Board of Directors of ImmunoGen, Inc., Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee of the Board of Directors of GlycoMimetics, Inc., and on the Board of Directors of Avacta Group plc. Dr. Goldberg also serves as a member of the National Board of Directors of the American Cancer Society (ACS), the ACS Eastern New England Area Board and the ACS New England Division Board. Dr. Goldberg received an A.B. in biochemical sciences from Harvard College and an M.D. from Harvard Medical School.
Mark Goldberg, M.D. has served as a member of our Board of Directors since June 2015. Since 2018, Dr. Goldberg has served as an advisor at CANbridge Life Sciences Ltd., a biopharmaceutical company focused on rare diseases and rare oncology, and served as Acting Chief Medical Officer from 2015 to 2018. Previously, he served as an advisor and held various executive positions of increasing responsibility at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals, Inc., including Executive Vice President, Medical and Regulatory Strategy. Earlier in his career, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme from November 1996 to July 2011, including as Senior Vice President, Clinical Development and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of the Early Product Development Board. Dr. Goldberg has been a faculty member of the Hematology Division at Brigham and Women’s Hospital since 1987 and was a staff physician at the Dana-Farber Cancer Institute from 1996 to 2018. From 1996 to 2021, Dr. Goldberg was a part-time Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg currently serves as a member of the Compensation and Governance and Nominating Committees of the Board of Directors of ImmunoGen, Inc., Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee of the Board of Directors of GlycoMimetics, Inc., and on the Board of Directors of Avacta Group plc. Dr. Goldberg also serves as a member of the National Board of Directors of the American Cancer Society (ACS), the ACS Eastern New England Area Board and the ACS New England Division Board. Dr. Goldberg received an A.B. in biochemical sciences from Harvard College and an M.D. from Harvard Medical School.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Kate Haviland
President and Chief Executive Officer, Blueprint Medicines
Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in scaling high-growth organizations, strategic business development, portfolio strategy, investor relations, and commercial execution. Since April 2022, Kate has served as President and Chief Executive Officer of Blueprint Medicines. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she was the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including corporate development, corporate affairs, commercial strategy, international, technical operations, portfolio strategy and management, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics, as an independent director on the board of directors at Bicara Therapeutics, and as a member of the board of directors at Biotechnology Innovation Organization (BIO).
Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in scaling high-growth organizations, strategic business development, portfolio strategy, investor relations, and commercial execution. Since April 2022, Kate has served as President and Chief Executive Officer of Blueprint Medicines. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she was the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including corporate development, corporate affairs, commercial strategy, international, technical operations, portfolio strategy and management, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics, as an independent director on the board of directors at Bicara Therapeutics, and as a member of the board of directors at Biotechnology Innovation Organization (BIO).
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Nicholas Lydon, Ph.D.
Scientific Founder, Blueprint Medicines
Nicholas Lydon, Ph.D., FRS, is a scientific founder of Blueprint Medicines and has served as a member of our Board of Directors since April 2011. Dr. Lydon is a Co-Founder of IDRx, Inc., and he is a Co-Founder of Recludix Pharma Inc. and has served on its Board of Directors and as a scientific advisor since 2019. In addition, Dr. Lydon currently serves as Managing Member of Staurus Biopharma, LLC, a privately held biopharmaceutical company that he co-founded. Dr. Lydon is a co-founder of AnaptysBio Inc. and served as a scientific advisor and member of its Board of Directors between 2006 and 2019. From 2003 to 2011, Dr. Lydon served as a scientific advisor and member of the Board of Directors of Ambit Biosciences Corp., a biopharmaceutical company focused on kinase inhibitor therapeutics. From 2000 to 2002, Dr. Lydon served as Vice President, Small Molecule Drug Discovery at Amgen, Inc. Prior to joining Amgen, Dr. Lydon founded and served as Chief Executive Officer of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, which was acquired by Amgen in 2000. Prior to Kinetix Pharmaceuticals, Dr. Lydon worked for Ciba-Giegy AG (now Novartis AG), where he was responsible for the tyrosine protein kinase program, including the discovery and preclinical development of imatinib. Dr. Lydon has been awarded the Lasker-DeBakey Clinical Medical Research Award, the Kettering Prize from the General Motors Cancer Research Foundation and the Japan Prize for his role in the development of imatinib. Dr. Lydon received a B.S. in biochemistry and zoology from the University of Leeds, England, and received a Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.
Nicholas Lydon, Ph.D., FRS, is a scientific founder of Blueprint Medicines and has served as a member of our Board of Directors since April 2011. Dr. Lydon is a Co-Founder of IDRx, Inc., and he is a Co-Founder of Recludix Pharma Inc. and has served on its Board of Directors and as a scientific advisor since 2019. In addition, Dr. Lydon currently serves as Managing Member of Staurus Biopharma, LLC, a privately held biopharmaceutical company that he co-founded. Dr. Lydon is a co-founder of AnaptysBio Inc. and served as a scientific advisor and member of its Board of Directors between 2006 and 2019. From 2003 to 2011, Dr. Lydon served as a scientific advisor and member of the Board of Directors of Ambit Biosciences Corp., a biopharmaceutical company focused on kinase inhibitor therapeutics. From 2000 to 2002, Dr. Lydon served as Vice President, Small Molecule Drug Discovery at Amgen, Inc. Prior to joining Amgen, Dr. Lydon founded and served as Chief Executive Officer of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, which was acquired by Amgen in 2000. Prior to Kinetix Pharmaceuticals, Dr. Lydon worked for Ciba-Giegy AG (now Novartis AG), where he was responsible for the tyrosine protein kinase program, including the discovery and preclinical development of imatinib. Dr. Lydon has been awarded the Lasker-DeBakey Clinical Medical Research Award, the Kettering Prize from the General Motors Cancer Research Foundation and the Japan Prize for his role in the development of imatinib. Dr. Lydon received a B.S. in biochemistry and zoology from the University of Leeds, England, and received a Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Lynn Seely, M.D.
President and Chief Executive Officer, Lyell Immunopharma and Lead Independent Director, Blueprint Medicines
Lynn Seely, M.D., has served as a member of our Board of Directors since April 2016 and is the Chair of the Compensation Committee. Currently, Dr. Seely serves as President and Chief Executive Officer of Lyell Immunopharma, a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Previously, Dr. Seely was President, Chief Executive Officer and a member of the Board of Directors of Myovant Sciences, Inc. a biopharmaceutical company focused on developing and commercializing innovative therapies for women’s and men’s health. Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc, where she led development of XTANDI® (enzalutamide) from the first-in-human clinical trial through global approvals. Dr. Seely has held various finance positions at Anesiva, Inc. (formerly Corgentech Inc.), Cytyc Health Corporation and ProDuct Health. Dr. Seely began her career as Associate Director of Clinical Development at Chiron Corporation. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine, completed her residency and served as Chief Resident in internal medicine at Yale-New Haven Hospital, and completed a fellowship in endocrinology and metabolism at the University of California, San Diego.
Lynn Seely, M.D., has served as a member of our Board of Directors since April 2016 and is the Chair of the Compensation Committee. Currently, Dr. Seely serves as President and Chief Executive Officer of Lyell Immunopharma, a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Previously, Dr. Seely was President, Chief Executive Officer and a member of the Board of Directors of Myovant Sciences, Inc. a biopharmaceutical company focused on developing and commercializing innovative therapies for women’s and men’s health. Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc, where she led development of XTANDI® (enzalutamide) from the first-in-human clinical trial through global approvals. Dr. Seely has held various finance positions at Anesiva, Inc. (formerly Corgentech Inc.), Cytyc Health Corporation and ProDuct Health. Dr. Seely began her career as Associate Director of Clinical Development at Chiron Corporation. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine, completed her residency and served as Chief Resident in internal medicine at Yale-New Haven Hospital, and completed a fellowship in endocrinology and metabolism at the University of California, San Diego.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
John Tsai, M.D.
Chief Executive Officer, Forcefield Therapeutics
John Tsai, M.D., has served on our Board of Directors since January 2023. Dr. Tsai is the Chief Executive Officer of Forcefield Therapeutics and an executive partner at Syncona. Prior to this role, Dr. Tsai was President, Global Drug Development and Chief Medical Officer at Novartis, where he led the company’s development portfolio spanning 160 new projects and 500 clinical trials, as well as the team securing global approvals for 15 new medicines. Dr. Tsai has served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent the previous 11 years at Bristol-Myers Squibb. During his tenure at Bristol-Myers Squibb, Dr. Tsai held positions of increasing responsibility within the Medical and Drug Development organizations, including Head of Late Phase Development and Oncology Development Leader, Head of Worldwide Medical Affairs, Chief Medical Officer Europe, Head of U.S. Medical, and Vice-President, Cardiovascular and Metabolic Disease Area. Earlier in his career, Dr. Tsai held drug development roles at Pfizer and manufacturing roles at GE. Dr. Tsai received a B.S. in electrical engineering from Washington University in St. Louis and an M.D. from University of Louisville School of Medicine.
John Tsai, M.D., has served on our Board of Directors since January 2023. Dr. Tsai is the Chief Executive Officer of Forcefield Therapeutics and an executive partner at Syncona. Prior to this role, Dr. Tsai was President, Global Drug Development and Chief Medical Officer at Novartis, where he led the company’s development portfolio spanning 160 new projects and 500 clinical trials, as well as the team securing global approvals for 15 new medicines. Dr. Tsai has served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent the previous 11 years at Bristol-Myers Squibb. During his tenure at Bristol-Myers Squibb, Dr. Tsai held positions of increasing responsibility within the Medical and Drug Development organizations, including Head of Late Phase Development and Oncology Development Leader, Head of Worldwide Medical Affairs, Chief Medical Officer Europe, Head of U.S. Medical, and Vice-President, Cardiovascular and Metabolic Disease Area. Earlier in his career, Dr. Tsai held drug development roles at Pfizer and manufacturing roles at GE. Dr. Tsai received a B.S. in electrical engineering from Washington University in St. Louis and an M.D. from University of Louisville School of Medicine.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.
Scientific Advisory Board
George Demetri, M.D. (Chair)
Professor of Medicine, Harvard Medical School
Brian Druker, M.D.*
Chief Executive Officer, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research
Mark Goldberg, M.D.
Lecturer in Medicine, Harvard Medical School and Faculty Member, Hematology Division, Brigham and Women’s Hospital
Scott Lowe, Ph.D.*
Investigator, Howard Hughes Medical Institute and Chair, Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Nicholas Lydon, Ph.D.*
Scientific Founder, Blueprint Medicines
Charles L. Sawyers, M.D.*
Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and Investigator, Howard Hughes Medical Institute
*Scientific Founder of Blueprint Medicines
*Scientific Founder of Blueprint Medicines